Sarasota, FL — November 6, 2018 — InvestorsHub NewsWire — Kali, Inc. (USOTC: KALY) today announced plans to finalize the previously announced pending acquisition of NCM Biotech. Kali and NCM Biotech, have recently announced a letter of intent agreement regarding the pending acquisition. NCM Biotech is the developer and owner of a patented cannabis extraction process – U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.” Kali and NCM are meeting this week in Dallas to both consummate the acquisition an strategize with Puration, Inc. (PURA) and Nouveau Life Pharmaceuticals, Inc. on the recent formation of a joint venture (JV) company to develop cannabis pharmaceutical products. Kali has partnered with PURA and NOUV to form US Cannabis Health, a JV company formed for the development of cannabis pharmaceutical and wellness products. The cannabis pharmaceuticals market is forecasted to reach a $50 billion sales by 2029.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.